secwatch.observer — SEC 8-K summary
======================================

Issuer:     Axsome Therapeutics, Inc. (AXSM)
CIK:        0001579428
Form:       8-K
Filed at:   2022-11-07T23:59:59+00:00
Accession:  0000950170-22-022315
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Axsome Q3 2022: First Sunosi revenue $16.8M, Auvelity launched, net loss $44.8M
-------------------------------------------------------------------------------

- Sunosi U.S. net sales $16.8M (first reported by Axsome); total revenues $16.8M vs $0 prior year.
- Net loss $44.8M ($1.07/share) vs $34.9M ($0.93) in Q3 2021; R&D $14.9M, SG&A $40.9M.
- Cash $227.5M (vs $86.5M Dec 2021); expects cash to fund operations into 2025.
- Auvelity launched Oct 20, 2022 for MDD; field force with prior psychiatry experience engaging prescribers.
- Pipeline: AXS-07 NDA resubmission Q3 2023; AXS-05 ACCORD topline Q4 2022; solriamfetol ADHD trial Q4 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1579428/000095017022022315/0000950170-22-022315-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1579428/000095017022022315/axsm-20221107.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-022315

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer